Integrated Behavioral Health, Inc.

Integrated Behavioral Health, Inc., a for-profit Subchapter S corporation headquartered in Irvine, California, provides drug use surveillance, public health data licensing, and behavioral health research services to federal health agencies as a prime contractor (90% of recent awards). The vendor operates without set-aside designations, competing in full-and-open procurements under NAICS 541711 (Research and Development in the Physical, Engineering, and Life Sciences) and PSC Special Studies/Analysis — Scientific Data.

The vendor's customer base is highly concentrated within two agencies of the Department of Health and Human Services. The Food and Drug Administration accounts for six awards with $20.9 million combined potential value, while the Centers for Disease Control and Prevention Pittsburgh accounts for three awards with $7.5 million combined potential value, together representing 100% of the vendor's identified awards. This concentration reflects Integrated Behavioral Health's narrow but deep positioning in post-marketing drug surveillance and substance use disorder research.

The vendor holds an Indefinite Delivery Contract (75F40121D00032) with the FDA awarded September 30, 2026, carrying an $8.5 million ceiling through September 29, 2031. This is a multiple-award vehicle (maximum two IDIQs) supporting Non-Medical Use Surveillance services, delivering post-marketing surveillance data reporting and analysis on prescription and over-the-counter drug nonmedical use, illicit substance use, and emerging regulatory substances. The IDIQ requires the vendor to maintain access to a minimum of 50,000 individual subjects entering or being assessed for substance use disorder treatment with geographic diversity across all four U.S. census regions and a minimum of ten years of historical data from 2016 to present. Compensation is structured as fully burdened hourly labor rates across seven specified categories: Project Manager, Senior Computer Systems Analyst, Statistician, Pharmacist, Epidemiologist, Survey Scientist, and Subject Matter Expert. The FDA anticipates issuing 2–4 task orders over the contract life with 0–2 ad hoc analytic requests annually.

Recent representative prime work includes a $1.05 million FDA delivery order (September 2022, ultimate completion September 28, 2027) to conduct research understanding the prevalence, experiences, knowledge, and perceptions of falsified and unapproved pharmaceuticals among populations being assessed for or entering substance use disorder treatment; a $3 million CDC Purchase Order (September 2023, ultimate completion April 22, 2025) for data licensing in support of the National Violent Death Reporting System; a $309,073.26 FDA delivery order (September 2026) for post-marketing prescription drug abuse surveillance data under Executive Order 14398; and a $46,348.98 FDA delivery order (September 2026) for redefining nonmedical use of buprenorphine and methadone in the Addiction Severity Index-Multimedia Version clinical assessment tool. Work is performed at Silver Spring, Maryland and subordinate locations with geographic diversity.

Activity shows recent acceleration — one award in 2020, two in 2021, one in 2022, one in 2023, and four in 2026 — though the combined dollars obligated ($49.2 million) exceed the combined potential value ($28.4 million) by 73%, indicating invoiced or obligated work has outpaced ceiling values on recent awards. Four awards (combined potential value $2.4 million) face ultimate completion inside the next twenty-four months, creating recompete exposure. The vendor holds one subcontract award (May 2026) providing services in support of the Military OneSource Program for military members and their families under a DoD employee assistance program.